Alkomex GBN Pharma Focuses on Nutraceuticals & Functional Foods in India

New Delhi:  Alkomex GBN Pharma Group looks to tap nutraceutical and functional food segments to drive its growth in the Indian market, according to a company official.

The global pharma company aims for a significant increase in revenue in India by tapping into the nutraceutical and functional food segments, Alkomex GBN Pharma Group Scientific Advisor Dr. Sanjay Agrawal said.

Alkomex is also looking to launch innovative products backed by regional research to expand business in the country.

The company, part of Alkomex GBN, caters to the Indian market with a range of products, including ophthalmic solutions, dermatological products, multivitamins and nutritional supplements, and probiotics.

It has formed partnerships with companies like Danone Group to deliver high-quality healthcare products in the country. It also leverages contract manufacturing to meet the growing demand for these products.

To boost its presence, the company appointed Agrawal, a leading expert in health management and nutraceuticals, as its Scientific Advisor in November last year.

Alkomex GBN in November 2024 announced a global growth and dual-division strategy, focusing on expanding its footprint in Asia and other international markets. Under the strategy, its pharmaceutical division would drive advancements in ophthalmic, dermatological, and healthcare solutions, and the industrial division would provide innovative packaging and industrial materials.

Related Posts

Spurious drug probe: SIT raids medical store in Bengaluru, detains proprietor

Bengaluru: In a major breakthrough in the illegal pharmaceutical network operating in Karnataka, investigators from the Special Investigation Team (SIT) raided Krupa Health Care at Minerva Circle, seizing a cache…

US FDA grants orphan drug designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart to treat endogenous Cushing’s syndrome

Lundbeck, a biopharmaceutical company focusing exclusively on brain health, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to asedebart (Lu AG13909), Lundbeck’s novel…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Spurious drug probe: SIT raids medical store in Bengaluru, detains proprietor

Spurious drug probe: SIT raids medical store in Bengaluru, detains proprietor

US FDA grants orphan drug designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart to treat endogenous Cushing’s syndrome

US FDA grants orphan drug designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart to treat endogenous Cushing’s syndrome

Fujifilm India installs Echelon Smart MRI at Jansons Health in Erode

Fujifilm India installs Echelon Smart MRI at Jansons Health in Erode

Rajasthan to prepare ‘Narcotics Control Vision 2026-29’ to curb drug abuse and trafficking

Rajasthan to prepare ‘Narcotics Control Vision 2026-29’ to curb drug abuse and trafficking

Bracco Imaging expands BubbleGen cell selection with CD3+ T Cell Isolation Kit

Bracco Imaging expands BubbleGen cell selection with CD3+ T Cell Isolation Kit

5 medicine samples found substandard in Bhiwadi warehouse raid; probe launched

5 medicine samples found substandard in Bhiwadi warehouse raid; probe launched